Table 2.

Univariate and multivariate analysis for cumulative incidence of CMV reactivation

VariablesUnivariate analysisMultivariate analysis
HR95% CIPHR95% CIP
Underlying disease*       
 Acute lymphoblastic leukemia 0.93 0.87-0.99 .035 1.01 0.94-1.09 .79 
 Myelodysplastic syndromes 1.06 0.99-1.14 .071 1.03 0.96-1.10 .38 
 CML 0.83 0.72-0.95 .009 0.89 0.78-1.02 .10 
Patient age ≥50 y 1.38 1.31-1.46 <.001 1.30 1.22-1.38 <.001 
Donor age ≥50 y 0.87 0.80-0.94 <.001 0.97 0.88-1.07 .52 
Patient sex, male 1.01 0.95-1.06 .85 0.97 0.90-1.04 .35 
Donor sex, male 1.03 0.98-1.09 .22 1.07 0.99-1.16 .10 
Female donor/male recipient 1.00 0.94-1.07 .89 1.07 0.96-1.19 .22 
Recipient/donor CMV serology†       
 Positive/positive 2.17 1.95-2.42 <.001 2.20 1.96-2.47 <.001 
 Positive/negative 2.63 2.36-2.93 <.001 2.48 2.22-2.76 <.001 
 Negative/positive 1.11 0.95-1.30 .20 1.16 0.98-1.36 .080 
Disease risk (high) 1.04 0.99-1.09 .15 0.94 0.89-1.00 0.042 
PS (poor) 1.03 0.94-1.14 .51 0.95 0.86-1.05 .30 
Stem cell source‡       
 PBSC 0.88 0.82-0.95 <.001 1.02 0.91-1.14 .72 
 CB 1.09 1.03-1.15 .005 0.86 0.79-0.93 <.001 
Transplant from unrelated donor 1.29 1.21-1.37 <.001 1.27 1.13-1.42 <0.001 
HLA disparity (mismatch) 1.51 1.43-1.59 <.001 1.46 1.37-1.55 <.001 
Conditioning (reduced intensity) 1.25 1.18-1.32 <.001 1.03 0.97-1.10 .34 
TBI 1.06 1.01-1.13 .032 1.12 1.06-1.19 <.001 
GVHD prophylaxis       
 Tacrolimus-based regimen§ 1.13 1.06-1.19 <.001 0.90 0.84-0.96 .002 
 Mycophenolate mofetil use 0.97 0.89-1.05 .41 0.88 0.80-0.96 .006 
 TCD in vivo 1.73 1.57-1.89 <.001 1.64 1.48-1.82 <.001 
Transplant year (2004-2010) 1.10 1.04-1.16 <.001 1.12 1.06-1.18 <.001 
VariablesUnivariate analysisMultivariate analysis
HR95% CIPHR95% CIP
Underlying disease*       
 Acute lymphoblastic leukemia 0.93 0.87-0.99 .035 1.01 0.94-1.09 .79 
 Myelodysplastic syndromes 1.06 0.99-1.14 .071 1.03 0.96-1.10 .38 
 CML 0.83 0.72-0.95 .009 0.89 0.78-1.02 .10 
Patient age ≥50 y 1.38 1.31-1.46 <.001 1.30 1.22-1.38 <.001 
Donor age ≥50 y 0.87 0.80-0.94 <.001 0.97 0.88-1.07 .52 
Patient sex, male 1.01 0.95-1.06 .85 0.97 0.90-1.04 .35 
Donor sex, male 1.03 0.98-1.09 .22 1.07 0.99-1.16 .10 
Female donor/male recipient 1.00 0.94-1.07 .89 1.07 0.96-1.19 .22 
Recipient/donor CMV serology†       
 Positive/positive 2.17 1.95-2.42 <.001 2.20 1.96-2.47 <.001 
 Positive/negative 2.63 2.36-2.93 <.001 2.48 2.22-2.76 <.001 
 Negative/positive 1.11 0.95-1.30 .20 1.16 0.98-1.36 .080 
Disease risk (high) 1.04 0.99-1.09 .15 0.94 0.89-1.00 0.042 
PS (poor) 1.03 0.94-1.14 .51 0.95 0.86-1.05 .30 
Stem cell source‡       
 PBSC 0.88 0.82-0.95 <.001 1.02 0.91-1.14 .72 
 CB 1.09 1.03-1.15 .005 0.86 0.79-0.93 <.001 
Transplant from unrelated donor 1.29 1.21-1.37 <.001 1.27 1.13-1.42 <0.001 
HLA disparity (mismatch) 1.51 1.43-1.59 <.001 1.46 1.37-1.55 <.001 
Conditioning (reduced intensity) 1.25 1.18-1.32 <.001 1.03 0.97-1.10 .34 
TBI 1.06 1.01-1.13 .032 1.12 1.06-1.19 <.001 
GVHD prophylaxis       
 Tacrolimus-based regimen§ 1.13 1.06-1.19 <.001 0.90 0.84-0.96 .002 
 Mycophenolate mofetil use 0.97 0.89-1.05 .41 0.88 0.80-0.96 .006 
 TCD in vivo 1.73 1.57-1.89 <.001 1.64 1.48-1.82 <.001 
Transplant year (2004-2010) 1.10 1.04-1.16 <.001 1.12 1.06-1.18 <.001 
*

Acute myeloid leukemia was treated as reference.

†

Negative/negative CMV serology was treated as reference.

‡

Bone marrow transplantation was treated as reference.

§

Cyclosporine-based regimen was treated as reference.

​Transplant year (2011-2016) was treated as reference.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal